ZA201704320B - Novel proteins specific for angiogenesis - Google Patents
Novel proteins specific for angiogenesisInfo
- Publication number
- ZA201704320B ZA201704320B ZA2017/04320A ZA201704320A ZA201704320B ZA 201704320 B ZA201704320 B ZA 201704320B ZA 2017/04320 A ZA2017/04320 A ZA 2017/04320A ZA 201704320 A ZA201704320 A ZA 201704320A ZA 201704320 B ZA201704320 B ZA 201704320B
- Authority
- ZA
- South Africa
- Prior art keywords
- angiogenesis
- novel proteins
- proteins specific
- specific
- novel
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152826 | 2015-01-28 | ||
| PCT/EP2016/051657 WO2016120307A1 (en) | 2015-01-28 | 2016-01-27 | Novel proteins specific for angiogenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201704320B true ZA201704320B (en) | 2023-07-26 |
Family
ID=52396588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/04320A ZA201704320B (en) | 2015-01-28 | 2017-06-26 | Novel proteins specific for angiogenesis |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10526382B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3250586B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6839087B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170105609A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107207574A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016212087B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017015773A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2973640A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3250586T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX384075B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2720688C2 (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201705278QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016120307A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201704320B (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2564125C2 (ru) | 2009-12-07 | 2015-09-27 | Пирис Аг | Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени |
| EP2920202B1 (en) | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| SG10201912019WA (en) | 2014-05-22 | 2020-02-27 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA2973640A1 (en) | 2015-01-28 | 2016-08-04 | Rachida Siham Bel Aiba | Novel proteins specific for angiogenesis |
| DK3292137T3 (da) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| BR112017020434A2 (pt) | 2015-05-04 | 2018-06-26 | Pieris Pharmaceuticals Gmbh | polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2 |
| MX390894B (es) | 2015-05-18 | 2025-03-21 | Pieris Pharmaceuticals Gmbh | Polipéptido de fusión anti-cáncer. |
| KR20180008649A (ko) | 2015-05-18 | 2018-01-24 | 피어이스 파마슈티컬즈 게엠베하 | 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인 |
| EA035586B1 (ru) * | 2015-11-30 | 2020-07-10 | Пиерис Острелиа Пти Лтд. | Новые антиангиогенные слитые белки |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| CA3127973A1 (en) * | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| AU2021285201A1 (en) | 2020-06-05 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1BB |
| EP4215204A1 (en) * | 2022-01-24 | 2023-07-26 | Universitat Pompeu Fabra | Human neutrophil gelatinase-associated lipocalin derived from recombinant bacteria and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3779221D1 (de) | 1986-08-19 | 1992-06-25 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| ES2245780T3 (es) | 1994-05-18 | 2006-01-16 | Nektar Therapeutics | Metodos y composiciones para la formulacion de interferones como un polvo seco. |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| KR20010052622A (ko) | 1998-06-08 | 2001-06-25 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| CA2702611A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| SG172737A1 (en) * | 2008-01-30 | 2011-07-28 | Pieris Ag | Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinaseand methods for obtaining the same |
| US8420051B2 (en) * | 2008-06-24 | 2013-04-16 | Technische Universitaet Meunchen | Muteins of hNGAL and related proteins with affinity for a given target |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| RU2564125C2 (ru) * | 2009-12-07 | 2015-09-27 | Пирис Аг | Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени |
| SG187695A1 (en) | 2010-08-16 | 2013-03-28 | Pieris Ag | Binding proteins for hepcidin |
| US9260492B2 (en) | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| EP2920202B1 (en) * | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| GB201223053D0 (en) * | 2012-12-20 | 2013-02-06 | Medical Res Council | Receptor |
| CA2973640A1 (en) | 2015-01-28 | 2016-08-04 | Rachida Siham Bel Aiba | Novel proteins specific for angiogenesis |
| CA2976687A1 (en) | 2015-02-18 | 2016-08-25 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| DK3292137T3 (da) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| KR20180008649A (ko) | 2015-05-18 | 2018-01-24 | 피어이스 파마슈티컬즈 게엠베하 | 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2016
- 2016-01-27 CA CA2973640A patent/CA2973640A1/en active Pending
- 2016-01-27 JP JP2017539548A patent/JP6839087B2/ja not_active Expired - Fee Related
- 2016-01-27 MX MX2017009767A patent/MX384075B/es unknown
- 2016-01-27 BR BR112017015773-0A patent/BR112017015773A2/pt not_active Application Discontinuation
- 2016-01-27 CN CN201680007089.1A patent/CN107207574A/zh active Pending
- 2016-01-27 EP EP16703451.1A patent/EP3250586B1/en active Active
- 2016-01-27 SG SG11201705278QA patent/SG11201705278QA/en unknown
- 2016-01-27 US US15/546,609 patent/US10526382B2/en active Active
- 2016-01-27 AU AU2016212087A patent/AU2016212087B2/en not_active Ceased
- 2016-01-27 DK DK16703451.1T patent/DK3250586T3/da active
- 2016-01-27 WO PCT/EP2016/051657 patent/WO2016120307A1/en not_active Ceased
- 2016-01-27 SG SG10201906859PA patent/SG10201906859PA/en unknown
- 2016-01-27 RU RU2017128105A patent/RU2720688C2/ru active
- 2016-01-27 KR KR1020177023448A patent/KR20170105609A/ko not_active Ceased
-
2017
- 2017-06-26 ZA ZA2017/04320A patent/ZA201704320B/en unknown
-
2019
- 2019-11-13 US US16/682,499 patent/US11034738B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017009767A (es) | 2018-08-15 |
| JP6839087B2 (ja) | 2021-03-03 |
| SG10201906859PA (en) | 2019-08-27 |
| US11034738B2 (en) | 2021-06-15 |
| WO2016120307A1 (en) | 2016-08-04 |
| EP3250586A1 (en) | 2017-12-06 |
| DK3250586T3 (da) | 2021-12-06 |
| EP3250586B1 (en) | 2021-10-27 |
| JP2018509887A (ja) | 2018-04-12 |
| AU2016212087A1 (en) | 2017-07-27 |
| RU2017128105A (ru) | 2019-03-05 |
| AU2016212087B2 (en) | 2019-11-07 |
| RU2017128105A3 (cg-RX-API-DMAC7.html) | 2019-07-17 |
| US20200140501A1 (en) | 2020-05-07 |
| SG11201705278QA (en) | 2017-07-28 |
| US20180016312A1 (en) | 2018-01-18 |
| KR20170105609A (ko) | 2017-09-19 |
| BR112017015773A2 (pt) | 2018-03-27 |
| MX384075B (es) | 2025-03-14 |
| CA2973640A1 (en) | 2016-08-04 |
| US10526382B2 (en) | 2020-01-07 |
| RU2720688C2 (ru) | 2020-05-12 |
| CN107207574A (zh) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201704320B (en) | Novel proteins specific for angiogenesis | |
| IL255767A (en) | New polypeptides | |
| ZA201705960B (en) | Proteins specific for cd137 | |
| GB201502305D0 (en) | Protein | |
| GB201502306D0 (en) | Protein | |
| GB201521393D0 (en) | Antibodies | |
| GB201508337D0 (en) | Novel peptides | |
| GB201418713D0 (en) | Bindings Proteins | |
| GB201608197D0 (en) | Novel proteins | |
| GB201515745D0 (en) | Proteins | |
| GB201511787D0 (en) | Proteins | |
| IL253635A0 (en) | Cyclopropanebenzofuranyl pyridopyrazinedione type compounds | |
| ZA201705934B (en) | Peptides for inhibiting angiogenesis | |
| GB201513033D0 (en) | Proteins | |
| PT3253769T (pt) | Novos polimorfos | |
| GB201522610D0 (en) | Protein | |
| IL246533A0 (en) | new proteins | |
| GB201503438D0 (en) | Antibodies | |
| GB201515245D0 (en) | Novel polypeptides | |
| GB201515744D0 (en) | Proteins | |
| GB201503778D0 (en) | Proteins | |
| GB201412797D0 (en) | Proteins | |
| GB201412649D0 (en) | Proteins | |
| GB201412646D0 (en) | Proteins | |
| GB201412648D0 (en) | Proteins |